215 related articles for article (PubMed ID: 32101576)
21. Identification of Serum miRNAs as Effective Diagnostic Biomarkers for Distinguishing Primary Central Nervous System Lymphoma from Glioma.
Si PP; Zhou XH; Qu ZZ
J Immunol Res; 2022; 2022():5052609. PubMed ID: 35497882
[TBL] [Abstract][Full Text] [Related]
22. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
23. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
24. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
[TBL] [Abstract][Full Text] [Related]
25. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
26. Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients.
Zhang C; Zhang CD; Ma MH; Dai DQ
World J Gastroenterol; 2018 Mar; 24(11):1206-1215. PubMed ID: 29568201
[TBL] [Abstract][Full Text] [Related]
27. Identification of microRNAs as novel biomarkers for esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas (TCGA) and bioinformatics.
Li CY; Zhang WW; Xiang JL; Wang XH; Li J; Wang JL
Chin Med J (Engl); 2019 Sep; 132(18):2213-2222. PubMed ID: 31490264
[TBL] [Abstract][Full Text] [Related]
28. Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer.
Tang J; Ma W; Zeng Q; Tan J; Cao K; Luo L
Dis Markers; 2019; 2019():3815952. PubMed ID: 31976020
[TBL] [Abstract][Full Text] [Related]
29. Bioinformatics analyses of significant prognostic risk markers for thyroid papillary carcinoma.
Min XS; Huang P; Liu X; Dong C; Jiang XL; Yuan ZT; Mao LF; Chang S
Tumour Biol; 2015 Sep; 36(10):7457-63. PubMed ID: 25908172
[TBL] [Abstract][Full Text] [Related]
30. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
[TBL] [Abstract][Full Text] [Related]
31. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.
Lu M; Kong X; Wang H; Huang G; Ye C; He Z
Oncotarget; 2017 Jan; 8(5):8775-8784. PubMed ID: 28060739
[TBL] [Abstract][Full Text] [Related]
32. Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.
Lai NS; Wu DG; Fang XG; Lin YC; Chen SS; Li ZB; Xu SS
Br J Cancer; 2015 Mar; 112(7):1241-6. PubMed ID: 25756397
[TBL] [Abstract][Full Text] [Related]
33. Screening of Target Genes and Regulatory Function of miRNAs as Prognostic Indicators for Prostate Cancer.
Xiaoli Z; Yawei W; Lianna L; Haifeng L; Hui Z
Med Sci Monit; 2015 Dec; 21():3748-59. PubMed ID: 26628405
[TBL] [Abstract][Full Text] [Related]
34. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma.
Sung CO; Kim SC; Karnan S; Karube K; Shin HJ; Nam DH; Suh YL; Kim SH; Kim JY; Kim SJ; Kim WS; Seto M; Ko YH
Blood; 2011 Jan; 117(4):1291-300. PubMed ID: 21088137
[TBL] [Abstract][Full Text] [Related]
35. Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma.
Kawaguchi A; Iwadate Y; Komohara Y; Sano M; Kajiwara K; Yajima N; Tsuchiya N; Homma J; Aoki H; Kobayashi T; Sakai Y; Hondoh H; Fujii Y; Kakuma T; Yamanaka R
Clin Cancer Res; 2012 Oct; 18(20):5672-81. PubMed ID: 22908096
[TBL] [Abstract][Full Text] [Related]
36. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
37. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
[TBL] [Abstract][Full Text] [Related]
38. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment Hemoglobin as an Independent Prognostic Factor in Primary Central Nervous System Lymphomas.
Le M; Garcilazo Y; Ibáñez-Juliá MJ; Younan N; Royer-Perron L; Benazra M; Mokhtari K; Houillier C; Hoang-Xuan K; Alentorn A
Oncologist; 2019 Sep; 24(9):e898-e904. PubMed ID: 30867243
[TBL] [Abstract][Full Text] [Related]
40. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma.
Takashima Y; Kawaguchi A; Fukai J; Iwadate Y; Kajiwara K; Hondoh H; Yamanaka R
PLoS One; 2021; 16(6):e0251272. PubMed ID: 34166375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]